Autonomix Medical, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
AMIX Nasdaq 3840 autonomix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Autonomix Medical, Inc.

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study - Jun 30th, 2025 6:30 am
Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology - Jun 27th, 2025 6:00 am
Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain - Jun 5th, 2025 6:45 am
AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech - May 22nd, 2025 9:39 am
Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology - May 15th, 2025 6:30 am
Autonomix CEO Brad Hauser to Present at Virtual Investor’s Closing Bell Event - May 14th, 2025 7:20 am
Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market - May 13th, 2025 7:20 am
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain - May 5th, 2025 6:30 am
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - May 1st, 2025 7:25 am
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain - Apr 30th, 2025 6:15 am
Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR - Apr 24th, 2025 6:30 am
Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 17th, 2025 3:00 pm
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology - Apr 16th, 2025 6:30 am
Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain - Apr 8th, 2025 6:15 am
Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO) - Apr 3rd, 2025 6:30 am
Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology - Mar 20th, 2025 6:30 am
Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation - Mar 14th, 2025 6:30 am
Autonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting - Mar 6th, 2025 7:00 am
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the LSI USA ’25 Emerging Medtech Summit - Feb 26th, 2025 7:00 am
Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting - Feb 20th, 2025 6:30 am